Illicitly manufactured fentanyl and amphetamine-type stimulants are major contributors to the opioid crisis in North America.

Grail Inc. soared by 379.5 percent in 2025, with the rally primarily boosted by a combination of bullish analyst ratings and ...

Pathophysiologic biomarkers for chronic spontaneous urticaria (CSU) are emerging, which can help better target therapies for ...

A retrospective single-centre study finds that a dual-energy CT protocol is non-inferior to a conventional triphasic CT ...

This population-based study used plasma pTau217 to estimate how common Alzheimer’s disease neuropathological changes are across age and cognitive status in a Norwegian community cohort. Prevalence ...

TLX591-CDx (Illuccix® in approved jurisdictions, 68 Ga-PSMA-11 ): Positive data from Phase 3 study in Chinese patients provides the basis for near-term NDA submission in China.

The integration of PD-1 inhibitors into standard chemotherapy and radiotherapy regimens has revolutionized nasopharyngeal ...

Surgical site infections (SSIs), particularly intra-abdominal (IAB) infections, are challenging to identify and remain a ...

Researchers developed and validated a machine-learning algorithm for predicting nutritional risk in patients with nasopharyngeal carcinoma.

The ASX rose by around lunch in the eastern states after Wall Street steadied nerves. Money was flowing back into miners and ...

Grail Inc. (NASDAQ:GRAL) is one of the best emerging technology stocks to invest in. On December 1, Morgan Stanley assumed coverage of Grail with an Equal Weight rating and a price target of $110, ...

Platinum-resistant recurrent epithelial ovarian cancer carries a bleak prognosis, with single-agent chemotherapy yielding ...